BAFF CAR-T Cells (LMY-920) for Systemic Lupus Erythematosus - Trial NCT06340750
Access comprehensive clinical trial information for NCT06340750 through Pure Global AI's free database. This Phase 1 trial is sponsored by Luminary Therapeutics and is currently Not yet recruiting. The study focuses on Systemic Lupus Erythematosus. Target enrollment is 18 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Luminary Therapeutics
Timeline & Enrollment
Phase 1
Jun 01, 2024
Apr 15, 2026
Primary Outcome
Safety of the Treatment,Recommended Phase 2 Dose (RP2D)
Summary
This phase 1 study seeks to examine the safety and recommended phase 2 dose (RP2D) of
 BAFF-ligand CAR-T cells (LMY-920) in adult patients with refractory systemic lupus
 erythematosus (SLE). It is hypothesized that BAFF CAR-T cells will be safe and will improve
 SLE disease activity scores.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06340750
Non-Device Trial